How GLP-1 Drugs Are Reshaping the Food and Snack Industry
Food and beverage companies have publicly acknowledged shifting product strategy in response to GLP-1 drugs' effect on consumer appetite and purchasing.
By the GLP Semaglutide editorial team · Last updated February 12, 2026
Several major food and beverage companies have discussed GLP-1 drug adoption as a factor in earnings calls and strategy communications, citing changes in portion sizing, snacking frequency, and category mix among consumers using these medications.
Still an emerging, contested data picture
Much of the reporting on GLP-1's effect on food purchasing relies on retail sales data and consumer surveys rather than controlled studies, and the scale of the effect is debated among industry analysts.
Beyond snacking
Reporting has also touched on restaurant portion sizes and menu strategy, though this remains a business-trends story more than a clinical one — worth reading with the same sourcing scrutiny as any market-trend reporting.
Primary sources